Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals.
Nicholas Richardson, DO, MPH
Advertisement
vice president of clinical development, Precision for Medicine, and former FDA deputy director for the Division of Hematologic Malignancies.
Articles by Nicholas Richardson, DO, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
2
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
3
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
4
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
5